New Drug ApprovalSchizophreniaMental Health
Cobenfy: The First New Schizophrenia Drug Class in Decades
For more than 70 years, every antipsychotic medication on the market has worked by blocking dopamine receptors. That changed in September 2024 when the FDA approved Cobenfy, a combination of xanomelin
PlusVirtual TeamNov 11, 2024